antimotility agent loperamide have been recommended [6] [7] [8] .
Fluoroquinolones have been considered to be first-line antibiotic therapy. However, because of increasing rates of fluoroquinolone resistance and potential adverse effects in selected patient populations, other antibiotics are now being recommended. Rifaximin has recently been approved for use in treating E. coli-induced, noninvasive TD and is recommended for travel to areas where ETEC is predominant, such as Mexico [9, 10] . It is not yet clear how well rifaximin will work against invasive pathogens, such as Campylobacter and Shigella species; therefore, it cannot be recommended for areas where these invasive pathogens have been shown to frequently cause diarrhea [11, 12] . Fluoroquinolone resistance among Campylobacter isolates has risen dramatically worldwide over the past 15 years; for example, 190% of isolates in Thailand are now fluoroquinolone resistant [13] [14] [15] . This fact, coupled with fluoroquinolones not being approved for use in children or pregnant women, has led to azithromycin frequently being recommended as empirical therapy for TD [6] [7] [8] .
In numerous studies, azithromycin has been as effective as a fluroquinolone for the treatment of infections due to Shigella species or ETEC and has been more effective than ciprofloxacin in the treatment of infection due to Campylobacter species [16] [17] [18] [19] .
Although previous studies have suggested that fluoroquinolones provide a more rapid response than azithromycin in the treatment of TD [17, 18] , these studies did not include the use of loperamide in the treatment regimen. Therefore, from May 2003 through August 2004, we conducted a double-blind, "dummy" pill-controlled trial comparing the efficacy of azithromycin plus loperamide versus levofloxacin plus loperamide in the treatment of acute noninflammatory diarrheal illness in military personnel at Incirlik Air Base, Turkey.
METHODS

Study site. Incirlik Air Base is an important base in the North
Atlantic Treaty Organization's Southern Region. It is located in the southeastern part of Turkey, ∼10 miles east of Adana, Turkey's fourth largest city, and ∼35 miles from the Mediterranean sea and several local resort areas. The village of Incirlik, the area surrounding the base, is an agricultural community with many fresh fruit and vegetable markets, small restaurants, and many small shops catering to the military population. Although food is provided by the US military on the base, many personnel enjoy exploring the region, and TD is a common problem.
Participants and study eligibility. This research was conducted in compliance with all federal regulations governing the protection of human subjects in research and was approved by the US Naval Medical Research Unit No. 3 (NAMRU-3) Institutional Review Board. Deployed US military personnel or beneficiaries aged у18 years who presented to the US Air Force Hospital (39th Medical Group) in Incirlik, Turkey, for evaluation of acute noninflammatory diarrhea were eligible for study enrollment. The study was presented in detail, and those electing to enroll were asked to provide written informed consent. Subjects were excluded from study participation if they were pregnant, had an allergy to a study medication, or had used antibiotics within the previous 72 h. Prior use of loperamide, bismuth subalicylate (Pepto-Bismol; Procter and Gamble), or other nonantibiotic therapy was not considered to be an exclusion for enrollment. Patients presenting with diarrhea were evaluated for study inclusion on the basis of their clinical symptoms. Those patients with gross blood evident in their stool at presentation, who reported seeing gross blood in their stool (dysentery), or who had a documented fever (oral temperature, у38ЊC; febrile diarrhea) were classified as having "inflammatory" diarrhea and were excluded from this study. All others were classified as having "noninflammatory" or "watery" diarrhea. Diarrhea was defined as у3 loose stools or у2 loose stools with у1 associated complaint (abdominal cramps, nausea, vomiting, or fever) within a 24-h period. Additional criteria included symptoms occurring р96 h prior to presentation and ambulatory management.
Treatment assignment, randomization, and blinding procedures. Subjects were randomized to receive either levofloxacin (500 mg administered in a single dose) plus loperamide (4 mg administered once, followed by 2 mg administered as needed up to 16 mg per day) or azithromycin (1000 mg administered in a single dose) plus loperamide (4 mg administered once, followed by 2 mg administered as needed up to 16 mg per day).
Study medications and identical-appearing placebos for both antibiotics were provided by Pfizer Pharmaceuticals Clinical Research Division. A computer-generated random-number code with a block size of 6 was also provided by Pfizer, and the blinding was maintained during the laboratory and analysis phases. Loperamide (2-mg capsules) was dispensed in bottles of 8 capsules from the hospital pharmacy. Volunteers were instructed to take 2 capsules along with their antibiotics at the initiation of therapy and then to use the loperamide as needed for treatment of persistent diarrhea (up to 8 capsules in a 24-h period).
Clinical monitoring. A standardized medical evaluation was performed, and rehydration therapy was provided as necessary. The initiation of therapy with the antibiotic and loperamide was directly observed, and volunteers were monitored for 30 min after dosing. Volunteers maintained a diary for 72 h to record the number of loose stools (per 6-h periods), additional symptoms, their ability to perform regular duties, and the use of additional loperamide. Clinical outcomes included clinical cure assessment (complete symptom resolution) at 24 h and 72 h, time to specific symptom resolution, time to resolution of associated symptoms, and assessment of any drugrelated adverse effects. A stool specimen was collected between day 5 and day 9 after enrollment to evaluate pathogen eradication. Stool microbiology. Stool specimens obtained at initial presentation and at the final follow-up visit (on days 5-9) were used for pretreatment and posttreatment microbiological testing, respectively. Culturing of stool specimens was performed on-site in the hospital microbiology laboratory using standard techniques, including the use of selective media for Campylobacter species (Campy-CVA; Oxoid), as described elsewhere [20] . In addition to any bacterial pathogen identified, 5 E. colilike colonies were randomly selected from each plate, aliquoted into a cryotube containing 1.0 mL of a 15% glyercol-trypiticase soy broth, and frozen at Ϫ70ЊC. Bacterial isolates were transported back to NAMRU-3 in Cairo, Egypt. On arrival at NAMRU-3, all E. coli-like colonies that were confirmed to be E. coli using the API 20E system (bioMérieux) were assayed for the production of either heat-labile or heat-stable toxin by GM1 ELISA [21] .
Campylobacter susceptibility was performed using azithromycin and levofloxacin E-tests, according to the manufacturer's instruction (AB Biodisk). Resistance criteria for Campylobacter species were a ciprofloxacin MIC у4 mg/mL Ϫ1 , a levofloxacin MIC у 4 mg/mL Ϫ1 , and an azithromycin MIC у8 mg/mL Ϫ1 .
The upper limit fluoroquinolone MIC was 64 mg/mL Ϫ1 (we coded this value for calculation purposes). Outcome measures. The primary outcome for this study was the time to diarrhea symptom resolution. The time to the last diarrheal (i.e., unformed) stool (TLUS) was defined as the time from initiation of antibiotic therapy until the passage of the last diarrheal stool (a loose or liquid stool meeting the pretreatment definition of diarrhea). TLUS was calculated in hours and based on the timing recorded in the diarrhea symptom diary. If the exact time of the last diarrheal stool was not recorded, the time was "imputed" by choosing the midpoint time for the 6-h block in which the stool was passed. TLUS time was imputed for 21 (10%) of the volunteers. Clinical cure was defined as the resolution of the passage of diarrheal stools and all associated symptoms (abdominal cramps, nausea, vomiting, or fever). In determining the TLUS and overall clinical cure, the presence of mild excessive gas or mild flatulence was not considered to be a symptom of continuing illness. A microbiological cure was defined as failure to isolate a bacterial pathogen detected on the pretreatment culture on the followup (day 5-9) stool culture. Statistical analysis. Based on past studies of treatment trials of antibiotic regimens adjuvanted with loperamide in regions where ETEC is predominant, we anticipated 24-h clinical cure rates of 75% (range, 60%-90%). Using the method of Blackwelder [22] to evaluate for a difference in equivalency between the 2 regimens, we estimated a need of 102 subjects (range, 49-131 subjects) in each arm to exclude a difference of 115% (80% power and 95% CI).
Baseline characteristics, adverse events, and summary followup findings were compared using parametric and nonparametric statistical tests, as appropriate. Differences in the frequencies of clinical cures and microbiologic eradication rates between study regimens were tested for significance using x 2 tests [23] . Differences in recovery times were evaluated using Kaplan-Meier analyses (for time to last diarrheal stool), logrank tests (for overall differences in response curves), and generalized Wilcoxon tests (for response curve differences emphasizing early treatment failures) [23] . Intention-to-treat and per-protocol analyses were conducted. All tests were 2-tailed, and P values !.05 were considered to be statistically significant (Bonferoni adjustments were made as appropriate for multiple comparisons). All statistical analyses were performed using SAS software, version 9 (SAS), and Stata software, version 9 (Stata).
RESULTS
Two hundred seven study-eligible personnel presenting with diarrhea met the definition for noninflammatory diarrhea and were randomized to receive azithromycin (106 patients) or levofloxacin (101 patients). The median age was 31 years; 65% of the subjects were male, 92% were members of the Air Force, and 75% were junior enlisted personnel. Median time in Turkey prior to study enrollment was 245 days, 31% of subjects reported a prior episode of TD that had occurred before arriving in Turkey, and 61% reported a prior episode of TD that had occurred while in Turkey. There was no statistically significant difference between the treatment groups with respect to several demographic characteristics, nor was there any difference with respect to clinical presentation (table 1) .
Volunteers typically had a minimal delay in presenting to the clinic after illness onset, with a mean duration of diarrhea of 25 h before presentation (interquartile range, 9.75-41 h). The illness was characterized with a mean of 7 episodes of loose or liquid stools in the 24 h preceding presentation. In addition, 26% of patients complained of fever, 81% had abdominal cramps, and 23% complained of vomiting. Three volunteers with "inflammatory diarrhea," as defined by documented fever or blood in stool, were inadvertently enrolled, but because their clinical results did not differ from those of the noninflammatory group, they were included in the analysis. Approximately 76% of the volunteers in all groups reported a reduction in activity or inability to work related to their illness, with 34% being removed from work for at least 1 day and ∼20% requiring intravenous hydration. Table 1 provides a comparison of the clinical manifestations, laboratory findings, and management at presentation for volunteers based on treatment assignment. Clinical characteristics at the time of study enrollment were equivalent among the 2 treatment groups, although prestudy, nonantibiotic self-treatment (with loperamide) was more common among the group randomized to receive azithromycin. However, use of loperamide prior to study entry was not associated with any difference in cure rate, compared with the group not using loperamide before enrollment.
An enteric pathogen was identified in 49.8% of samples, with ETEC being identified most frequently (table 2). Campylobacter species was the second most frequently identified pathogen. Antibiotic susceptibility testing was not performed for ETEC, but levofloxacin resistance was seen in 10 (77%) of 13 Campylobacter isolates (5 of 7 isolates in the levofloxacin arm and 5 of 6 isolates in the azithromycin arm), and azithromycin resistance was not seen. The numbers were not sufficient for statistical analysis of clinical course associated with resistance and treatment combinations. Only 3.4% of the subjects had multiple pathogens. No difference was noted in pathogen distribution between groups. One volunteer from the azithromycin group was lost to follow-up, but 99.5% of the volunteers returned for clinical visits. Posttreatment stool specimens were provided by 178 (83.1%) of the volunteers. Clinical outcomes. TLUS was shorter for the group randomized to receive levofloxacin (median TLUS, 3 h; interquartile range, 0-21 h) than for the group randomized to receive azithromycin (median TLUS, 13 h; interquartile range, 0-27 h), but the difference was not statistically significant (table  3 and figure 1) .
A few patients continued to have associated symptoms after resolution of diarrheal stools, but clinical resolution of all symptoms within 24 h occurred in 46.5% of the levofloxacin group and 39% of the azithromycin group. The median time to clinical cure of all symptoms was 2 days for both the levofloxacin and azithromycin groups ( ). At 72 h, 91.0% of the azith-P p .2 romycin group and 95.2% of the levofloxacin group had achieved clinical cure. The only noted adverse event was a higher rate of immediate postdosing nausea among participants in the azithromycin group (7.6%) than among participants in the levofloxacin group (1%; ; table 4). P p .04 Twenty-two volunteers (11 in each treatment arm) did not receive the 4-mg dose of loperamide with the initial dose of antibiotic. However, the per-protocol analysis did not differ from the results of the intention-to-treat analysis, with a median TLUS of 3 h (interquartile range, 0-19 h) for the levofloxacin group, compared with 12 h (interquartile range, 0-26 h) for the azithromycin group ( ); therefore, these 11 volunteers P p .2 were included in the final analysis.
Microbiological eradication of ETEC was noted in 85.4% of the volunteers who were treated with azithromycin and in 81% of those treated with levofloxacin ( ). However, Cam-P p .8 pylobacter species were eradicated from 66.6% of the azithromycin group but none of the levofloxacin group.
CONCLUSIONS
We were unable to detect a difference between 2 treatment regimens for noninflammatory diarrhea among a deployed US military population in Incirlik, Turkey, a region in which ETEC is predominant [24] . Although the median TLUS was shorter (3.1 h) with levofloxacin than with azithromycin (13.0 h), there was not a statistical difference in TLUS, in time to overall clinical cure, or in any associated measures of disease, such as time missed from work. Although we did not detect a statistical difference in TLUS between regimens, the study was not powered to detect this magnitude of difference in a time-to-event analysis. Had the study been powered on the basis of TLUS, a significant difference may have been detected. Of course, even though the difference was not statistically significant, a difference of 10 h could certainly be important to individual travelers.
Our findings are consistent with the earlier findings of Adachi et al. [18] involving persons from the United States travelling to Mexico. However, Adachi et al. [18] did not include loperamide in the treatment regimen and found a median TLUS of 22.3 h for treatment with azithromycin and 21.5 h for treatment with levofloxacin. In our study, the addition of loperamide decreased the median TLUS to just 13 h for patients receiving azithromycin and 3 h for patients receiving levofloxacin. Furthermore, more than one-quarter of individuals had immediate diarrhea resolution as measured by no additional diarrheal stools after dosing. Because the goal of self-treatment for TD is rapid resolution of symptoms so that the patient can return to the purpose of their travel, this improvement in time to symptom resolution is an important difference.
Nearly one-fifth of volunteers received intravenous rehydra-tion. This rate is higher than that typically seen in TD cases, but it is consistent with other military TD studies [19, 25] . Although bismuth subsalicylate has antimicrobial properties, prior use was not an exclusion for this study. There was no difference in the prior use of bismuth subsalicylate between treatment groups and no difference in outcomes between those that used bismuth subsalicylate prior to enrollment and those that did not. There was a difference in prior use of loperamide between the treatment groups, with more of the azithromycin group having used loperamide prior to enrollment. However, there was no difference in symptoms at enrollment or in clinical response between those who did and those who did not use loperamide prior to enrollment. After the initiation of antibiotic therapy, the effect of loperamide in the treatment regimen was clearly evident. The study was designed for each volunteer to take the randomized antibiotic together with 2 loperamide capsules. Early in the study, volunteers took the antibiotic under direct supervision of the investigators and then went to the pharmacy to receive the loperamide. Several of the early volunteers did not take the loperamide as instructed. When this was noted, the distribution of the medicines was altered to assure that the volunteers took the loperamide, but the early variance from the protocol allows us the opportunity to see the effect of the loperamide. Although the number of observations is too small to be conclusive, it appears that the addition of even 1 loperamide capsule decreases the TLUS. The addition of 2 loperamide capsules (4 mg total) showed a clear reduction in the TLUS (table 3) . However, the use of loperamide was not associated with decreased time to overall clinical cure, with the resolution of associated symptoms (e.g., cramps) occurring at a median of 2 days after treatment initiation independent of the number of loperamide capsules used.
Azithromycin (administered in a single 1000-mg dose) was selected for evaluation on the basis of demonstrated efficacy in treating dysentery due to Shigella species [16] and efficacy superior to that of azithromycin (500 mg administered daily for 3 days) in treating diarrhea associated with Campylobacter species [19] . Gastrointestinal adverse effects associated with azithromycin, particularly in treating a diarrheal illness with frequent baseline nausea and vomiting, were a concern. Tribble et al. [19] had shown that a single 1000-mg dose of azithromycin caused more nausea than either a 500-mg dose of azithromycin administered daily for 3 days or levofloxacin administered at a 500-mg dose daily for 3 days. We also found that azithromycin administered in a single 1000-mg dose caused more postdose nausea than did levofloxacin administered at a dose of 500 mg, but associated nausea was rare (occurring in 7.6% of patients). Postdose vomiting occurred in only 1 patient.
Tribble et al. [19] had also shown that azithromycin treatment resulted in a faster clinical cure than did levofloxacin treatment in Campylobacter species infection, especially when the Campylobacter strains demonstrated in vitro resistance to levofloxacin. Although Campylobacter species was the second most commonly isolated organism in this study, there were too few isolates to determine whether levofloxacin resistance correlated with worse outcome in the levofloxacin treatment group. Had there been fewer infections with levofloxacin-resistant Campylobacter, the difference between groups may have been greater in the favor of levofloxacin. However, considering ETEC isolates only, there was no difference between groups.
Azithromycin-based regimens may be the best choice for worldwide use for the self-treatment of TD. As with the fluoroquinolones, but unlike rifaximin, a single-dose regimen of azithromycin with loperamide has been shown to be effective and convenient, with minimal adverse effects. Although there have been reports of azithromycin resistance among some Campylobacter isolates [26] , these reports are much less common than the reports of increasing fluoroquinolone resistance, especially among Campylobacter isolates [10, 14] . Unlike rifaximin, azithromycin has been shown to be effective against both diarrheagenic E. coli and invasive pathogens, such as Shigella and Campylobacter species [16, 17] . This study demonstrates that, when combined with loperamide, treatment with azithromycin resolves TD as quickly as treatment with a fluoroquinolone.
Further studies should be conducted to resolve remaining questions related to the use of azithromycin for the treatment of TD. Among these questions are whether loperamide added to azithromycin (administered as a single 1000-mg dose) can be used to safely treat inflammatory diarrhea and whether, in an attempt to decrease adverse events, the dose of azithromycin can be divided to 500 mg given in 2 separate doses or reduced to 500 mg administered once without affecting treatment efficacy. Finally, the cost-effectiveness of azithromycin-based regimens, compared with that of alternative therapies, should be evaluated in both inflammatory and noninflammatory diarrhea. In summary, azithromycin in combination with loperamide was found to be highly effective for the treatment of TD and should be considered as an alternative to the use of a fluoroquinolone.
